64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)

NCT05633160 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Prostatic Neoplasms
Castration-Resistant

Interventions

DRUG: 64Cu-SAR-BBN
DRUG: 67Cu-SAR-BBN

Sponsor

Clarity Pharmaceuticals Ltd